BioCentury
ARTICLE | Clinical News

Aerosolized Alpha-1 antitrypsin: Completed Phase II enrollment

December 21, 2015 8:00 AM UTC

Kamada completed enrollment of 36 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 80 or 160 mg inhaled AAT twice daily for 12 weeks. The product uses the eFlow Nebulizer...